BACKGROUND AND OBJECTIVE: To investigate the efficacy of daunorubicin encapsulated in liposome as a drug delivery system to treat proliferative vitreoretinopathy (PVR). MATERIALS AND METHODS: An experimental PVR model was made in pigmented rabbits by injecting a suspension of conjunctival fibroblasts and platelet-rich plasma into the vitreous cavity. Daunorubicin was encapsulated in newly developed empty liposome by mixing the empty liposome with the drug solution. Studies were performed 24 hours, 1 week, and 1 month after injection of daunorubicin encapsulated in empty liposome in an experimental PVR model. RESULTS: Compared with the control PVR model, daunorubicin prevented the formation of PVR. Although pathologic changes were observed in the eyes injected with daunorubicin alone, there were no adverse effects observed in the eyes injected with daunorubicin encapsulated in empty liposome. CONCLUSIONS: Daunorubicin encapsulated in empty liposome seems to be effective in preventing PVR without causing any adverse effects to the retina.
BACKGROUND AND OBJECTIVE: To investigate the efficacy of daunorubicin encapsulated in liposome as a drug delivery system to treat proliferative vitreoretinopathy (PVR). MATERIALS AND METHODS: An experimental PVR model was made in pigmented rabbits by injecting a suspension of conjunctival fibroblasts and platelet-rich plasma into the vitreous cavity. Daunorubicin was encapsulated in newly developed empty liposome by mixing the empty liposome with the drug solution. Studies were performed 24 hours, 1 week, and 1 month after injection of daunorubicin encapsulated in empty liposome in an experimental PVR model. RESULTS: Compared with the control PVR model, daunorubicin prevented the formation of PVR. Although pathologic changes were observed in the eyes injected with daunorubicin alone, there were no adverse effects observed in the eyes injected with daunorubicin encapsulated in empty liposome. CONCLUSIONS:Daunorubicin encapsulated in empty liposome seems to be effective in preventing PVR without causing any adverse effects to the retina.
Authors: Martina Theresa Kralinger; Ulrike Stolba; Michaela Velikay; Stefan Egger; Susanne Binder; Andreas Wedrich; Anton Haas; Jean-Marie Parel; Gerhard Franz Kieselbach Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-04-28 Impact factor: 3.117
Authors: Jay Chhablani; Alejandra Nieto; Huiyuan Hou; Elizabeth C Wu; William R Freeman; Michael J Sailor; Lingyun Cheng Journal: Invest Ophthalmol Vis Sci Date: 2013-02-01 Impact factor: 4.799
Authors: Kathrin I Hartmann; Alejandra Nieto; Elizabeth C Wu; William R Freeman; Jae Suk Kim; Jay Chhablani; Michael J Sailor; Lingyun Cheng Journal: J Ocul Pharmacol Ther Date: 2013-02-28 Impact factor: 2.671
Authors: Renata Leite De Pinho Tavares; Mário Junqueira Nóbrega; Fernando Amaral Junqueira Nóbrega; Fernando José De Novelli; Carlos Augusto Cardim De Oliveira Journal: Int J Retina Vitreous Date: 2015-04-15